Cell surface anchoring antigen conjugates to treat cancer

Abstract

This disclosure provides cancer cell lysing agent, formulations comprising cancer cell lysing agent, and methods of using the same for treating cancer.

1 . A pharmaceutical composition comprising a cancer cell lysing agent and a Toll-like receptors (TLR) agonist, wherein the cancer cell lysing agent is selected from chemotherapy drug, cell lysing detergent and antibody against tumor cell surface antigen. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the Toll-like receptors (TLR) agonist is CpG, poly IC, imiquimod, or a mixture thereof. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the tumor cell surface antigen is selected from EGFR, HER2 and EpCAM. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the chemotherapy drug is selected from alkylating agent and anti-microtubule agent. 
     
     
         5 . A method of inhibiting tumor growth, comprising administering to a patient via intratumoral injection a composition containing therapeutically effective amount of cancer cell lysing agent and Toll-like receptors (TLR) agonist. 
     
     
         6 . The method of  claim 5 , wherein the Toll-like receptors (TLR) agonist is CpG, poly IC, imiquimod, or a mixture thereof. 
     
     
         7 . The method of  claim 5 , wherein the cancer cell lysing agent is selected from cell surface anchoring antigen conjugate, chemotherapy drug, cell lysing detergent and antibody against tumor cell surface antigen. 
     
     
         8 . The method of  claim 5 , wherein the cancer cell lysing agent is antibody against tumor antigen EGFR, HER2 or EpCAM. 
     
     
         9 . The method of  claim 5 , wherein the cancer cell lysing agent is alkylating agent or anti-microtubule agent.